BeOne Medicines AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Basel, Basel-Stadt and currently employs 11,075 full-time employees. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. The company is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Follow-Up Questions
BeOne Medicines AG의 CEO는 누구입니까?
Mr. John Oyler은 2010부터 회사에 합류한 BeOne Medicines AG의 Co-Founder입니다.
ONC 주식의 가격 성능은 어떻습니까?
ONC의 현재 가격은 $309.19이며, 전 거래일에 increased 0% 하였습니다.
BeOne Medicines AG의 주요 사업 주제나 업종은 무엇입니까?
BeOne Medicines AG은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
BeOne Medicines AG의 시가총액은 얼마입니까?
BeOne Medicines AG의 현재 시가총액은 $31.2B입니다
BeOne Medicines AG는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 7명의 분석가가 BeOne Medicines AG에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 11명의 매수, 1명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
